Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-market pilot reevaluation of Quanduzhong Capsule for mild essential hypertension
ChiCTR1900021690Phase 4Completed
- Sponsor
- Institute of Basic Theory for Chinese Medicine
- Start
- Oct 2018
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of Quanduzhong in essential hypertension (2 arms), sponsored by Institute of Basic Theory for Chinese Medicine. Primary endpoints: 24-hour ambulatory blood pressure and Office blood pressure. Started Oct 2018; status: completed.
02
Drugs
Quanduzhong
03
Conditions
essential hypertension
Beyond the preview
Go deeper on ChiCTR1900021690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021690.